Synchron, a US-based brain interface startup, supported by Jeff Bezos, the founder of Amazon, and Bill Gates, co-founder of Microsoft, is pioneering technology aimed at revolutionizing daily life for individuals with paralysis.
Transforming Lives Through Technology
According to CNBC, Synchron is among a new wave of companies exploring brain-computer interface (BCI) technology, with its flagship product, the Synchron Switch, offering remarkable capabilities. Implanted through blood vessels, the Synchron Switch enables patients to control technology using their thoughts alone.
Clinical Trials and Patient Experience
The experimental device has undergone trials involving three patients in the US and four in Australia. CEO Tom Oxley highlights the profound impact on patients, noting moments of joy and empowerment as individuals regain independence and engage with the world in ways previously unimaginable.
The Essence of Synchron’s Technology
Founded in 2012, Synchron represents a significant player in the burgeoning BCI industry. Its system deciphers brain signals, translating them into commands for external devices. The Synchron BCI, inserted via blood vessels, leverages what Oxley describes as the brain’s “natural highways” for seamless integration.
The Stentrode Innovation
At the heart of Synchron’s technology is the Stentrode, a device embedded with miniature sensors and delivered to a major vein near the brain’s motor cortex. Linked to an antenna beneath the skin, the Stentrode captures brain data and transmits it externally, enabling real-time communication with devices.
Empowering Patients with Paralysis
Synchron’s groundbreaking technology offers hope to individuals grappling with severe paralysis or conditions like amyotrophic lateral sclerosis (ALS). By enabling communication through typing, texting, or accessing social media, Synchron aims to enhance connectivity and quality of life for affected individuals.
Recognition and Support
In December of the previous year, Synchron secured a substantial $75 million funding round, with contributions from investment entities associated with Gates and Bezos. Recognizing its potential to address debilitating conditions, the US Food and Drug Administration granted Synchron the Breakthrough Device designation in August 2020.
Future Prospects
While Synchron has yet to generate revenue, its breakthroughs hold promise for transforming healthcare and enhancing the lives of millions worldwide. Although specifics regarding costs remain undisclosed, Synchron’s commitment to innovation underscores its dedication to improving patient outcomes and advancing neurotechnology.
